VRP.L Share News (VRP)

Verona Pharma doses first volunteers in 'RPL554' asthma trial

Verona Pharma said the first group of volunteers have been dosed with its new nebulised formulation of its RPL554 product as part of a Phase I/II clinical trial, which analysts said was a significant step. The AIM company said the study's main objective was to confirm the safety, tolerability and br

Verona Pharma Doses First Recruitments In RPL554 Clinical Trial

CORRECT: UK WINNERS & LOSERS: Intertek's Gain Is Inchcape's Loss On CEO Change

UK MIDDAY BRIEFING: Clothing Retailers Hit By Next Weather Warning

UK WINNERS & LOSERS: Intertek's Gain Is Inchcape's Loss On CEO Change

Verona Pharma Appoints Biresh Roy As Chief Financial Officer

Verona Shares Up As Data Shows Potential Of RPL554 In Cystic Fibrosis

Verona Pharma Posts Widened Loss As It Continues Drug Development

UK MIDDAY BRIEFING: ASOS Hit By Suspicious Warehouse Fire

UK WINNERS & LOSERS: Mining Companies Cheered By China PMI Data

UK MORNING BRIEFING: Shares Down As Iraq Fighting Lifts Oil Prices

Verona Pharma To Halt VRP700 Development After Trial Failure

Verona Pharma Loss Widens As It Continues To Develop Pipeline Drugs

LONDON (Alliance News) - Verona Pharma PLC Monday posted a widened pretax loss for 2013 as it continued to develop its two pipeline drugs towards commercialisation. Veron posted a pretax loss of GBP2.8 million, widened from a pretax loss of GBP2.6 million in 2012, as administration expense

UK MIDDAY BRIEFING: Boohoo.com Latest On IPO Catwalk

LONDON (Alliance News) - Online fashion retailer Boohoo.com, the latest UK retailer to firm up its initial public offering, has said it plans to raise GBP300 million in the AIM listing, giving it a higher-then-expected initial market capitalisation of GBP560 million.

Read more

UK WINNERS & LOSERS: Aviva Leads Blue-Chip Risers Again

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday. ------- FTSE 100 - WINNERS Aviva, up 4.2%. After closing as the blue-chip index's biggest riser on Thursday, Aviva is again the stand out performer Frid